Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Acadian Asset Management LLC

Acadian Asset Management LLC lowered its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 43.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 142,165 shares of the biotechnology company's stock after selling 108,327 shares during the period. Acadian Asset Management LLC owned 0.24% of Ascendis Pharma A/S worth $19,378,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vestal Point Capital LP bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at about $78,719,000. Price T Rowe Associates Inc. MD grew its position in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock valued at $269,374,000 after buying an additional 336,976 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Ascendis Pharma A/S by 20.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company's stock valued at $191,346,000 after buying an additional 254,749 shares during the last quarter. Westfield Capital Management Co. LP grew its position in shares of Ascendis Pharma A/S by 6.0% during the 4th quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company's stock valued at $507,658,000 after buying an additional 228,457 shares during the last quarter. Finally, Avoro Capital Advisors LLC grew its position in shares of Ascendis Pharma A/S by 5.6% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,966,666 shares of the biotechnology company's stock valued at $599,641,000 after buying an additional 211,111 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ASND shares. Stifel Nicolaus started coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a "buy" rating and a $200.00 price objective for the company. Cantor Fitzgerald lowered their price objective on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an "overweight" rating for the company in a research report on Wednesday, September 4th. Wells Fargo & Company reduced their target price on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an "overweight" rating for the company in a research note on Wednesday, September 4th. Citigroup reduced their target price on shares of Ascendis Pharma A/S from $193.00 to $178.00 and set a "buy" rating for the company in a research note on Wednesday, September 4th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Thursday, September 5th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S has an average rating of "Moderate Buy" and an average target price of $187.08.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND traded down $2.08 during trading on Tuesday, reaching $114.76. The company had a trading volume of 696,032 shares, compared to its average volume of 399,079. The firm's fifty day moving average is $134.04 and its 200 day moving average is $137.65. The firm has a market capitalization of $6.68 billion, a PE ratio of -12.16 and a beta of 0.63. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.